Application of LCN2 and NME3 in the diagnosis of intervertebral disc degeneration
By detecting the combined biomarkers of LCN2 and NME3 and combining them with machine learning algorithms, the subjectivity and accuracy issues in the diagnosis of intervertebral disc degeneration have been resolved, achieving earlier diagnosis with higher sensitivity and specificity.
Patent Information
- Application Number
- CN202611607612.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2026-03-26
- Filing Date
- 2026-10-16
- Publication Date
- 2026-11-17
AI Technical Summary
Existing diagnostic methods for intervertebral disc degeneration rely on imaging examinations, which are highly subjective, lack a unified grading scheme, and make it difficult to achieve accurate early diagnosis.
By using LCN2 and NME3 as combined biomarkers, a diagnostic model was constructed by detecting the levels of protein, DNA, and RNA in the sample and combining it with machine learning algorithms to achieve specific diagnosis of intervertebral disc degeneration.
It improves the sensitivity and specificity of early detection of intervertebral disc degeneration, and provides higher diagnostic accuracy, especially in the application of serum samples.
Smart Images

Figure CN123108142A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of LCN2 and NME3 in the diagnosis of intervertebral disc degeneration. Background Technology
[0002] Intervertebral disc degeneration is one of the most common degenerative diseases in orthopedics, and it is also the underlying pathology of many spinal diseases, including disc herniation, spinal stenosis, vertebral instability, and spondylolisthesis. These conditions have a profound impact on patients' quality of life. The intervertebral disc is mainly composed of the annulus fibrosus, nucleus pulposus, and cartilaginous endplates; abnormalities in the structure or function of any part can lead to disc degeneration. The occurrence and development of intervertebral disc degeneration are influenced by a variety of factors, including aging, mechanical stress, inflammation, trauma, and unhealthy lifestyle habits. However, these factors do not fully explain the complex process of intervertebral disc degeneration, and its pathogenesis remains not fully understood.
[0003] Currently, the diagnosis of intervertebral disc degeneration mainly relies on imaging examinations, including plain radiographs, computed tomography (CT) scans, and magnetic resonance imaging (MRI). These diagnostic methods all suffer from significant subjective biases; the interpretation of the same imaging results often varies from person to person, and a unified, universally accepted grading scheme is lacking. Disease biomarkers are molecular or biological characteristics in an organism that reflect the presence or progression of a specific disease. They can be various types of molecules, such as proteins, nucleic acids, and metabolites, and changes in their presence, expression levels, or activity states are usually correlated with specific disease states. The detection of these biomarkers can provide important information for early diagnosis, treatment efficacy evaluation, and disease progression detection. Therefore, research on biomarkers related to intervertebral disc degeneration has significant application prospects in the diagnosis, prediction, and treatment of intervertebral disc degeneration. Summary of the Invention
[0004] To overcome the shortcomings of the prior art, the present invention provides the following technical solution: The first aspect of the present invention provides the application of a reagent for detecting the expression level of a combined biomarker in a sample in the preparation of a product for diagnosing intervertebral disc degeneration, wherein the combined biomarker is NME3 and LCN2.
[0005] Furthermore, the reagents include reagents for detecting the protein expression levels of NME3 and LCN2 in the sample, reagents for detecting the DNA levels of NME3 and LCN2 in the sample, and reagents for detecting the RNA levels of NME3 and LCN2 in the sample.
[0006] Furthermore, the reagents for detecting the protein expression levels of NME3 and LCN2 in the sample include reagents for detecting the expression levels of NME3 and LCN2 using proteomics technology, and affinity reagents that specifically bind to NME3 or LCN2 proteins.
[0007] Furthermore, the affinity reagent includes antibodies, antibody fragments, or nucleic acid aptamers.
[0008] Furthermore, the reagents for detecting the DNA levels of NME3 and LCN2 in the sample include reagents for detecting the DNA levels of NME3 and LCN2 and their molecular modification levels (including DNA methylation level, DNA hydroxymethylation level, histone acetylation level, etc.).
[0009] Furthermore, the reagents for detecting the RNA levels of NME3 and LCN2 in the sample include reagents for detecting the expression levels of mRNA, lncRNA, circRNA, and / or miRNA of NME3 and LCN2 in the sample.
[0010] Furthermore, the intervertebral disc degeneration includes cervical intervertebral disc degeneration, lumbar intervertebral disc degeneration, and thoracic intervertebral disc degeneration.
[0011] Furthermore, the intervertebral disc degeneration is lumbar intervertebral disc degeneration.
[0012] Furthermore, the samples include tissues, cells, body fluids, and exosomes derived from the subject.
[0013] Furthermore, the body fluid samples include blood samples, serous cavity effusion samples, cerebrospinal fluid samples, lymph fluid samples, synovial fluid samples, urine samples, saliva samples, sputum samples, and tear samples.
[0014] Furthermore, the serous cavity effusion samples include pleural effusion samples, ascites samples, and pericardial effusion samples.
[0015] Furthermore, the sample is a blood sample from the subject.
[0016] Furthermore, the sample is a serum sample from the subject.
[0017] A second aspect of the present invention provides a product for diagnosing intervertebral disc degeneration, the product comprising the reagents described in the first aspect of the present invention.
[0018] Furthermore, the product includes reagent kits, chips, and test strips.
[0019] The third aspect of the present invention provides the application of combined biomarkers in constructing a diagnostic model for intervertebral disc degeneration, wherein the combined biomarkers are NME3 and LCN2.
[0020] The fourth aspect of the present invention provides a method for constructing a diagnostic model for intervertebral disc degeneration, the method comprising the steps of acquiring NME3 and LCN2 level data in a sample and inputting the data into a machine learning algorithm to construct a diagnostic model.
[0021] Furthermore, the method includes the following steps: dividing the NME3 and LCN2 level data into training and test sets, extracting the NME3 and LCN2 level data from the training set into the machine learning algorithm to construct a diagnostic model, and validating the model through the test set to evaluate its effectiveness.
[0022] Furthermore, the machine learning algorithm includes algorithmic models developed using various development tools.
[0023] Furthermore, the development tools include TensorFlow, Scikit-Learn, PyTorch, OpenNN, RapidMiner, Azure Machine Learning, Apache Mahout, Shogun, KNIME, Vertex AI, H2Oai, Anaconda, Keras, Tableau, Fast.ai, Catalyst, Amazon ML, MLJAR, and Spell.
[0024] Furthermore, the algorithm models include linear regression models, logistic regression models, Lasso regression models, Ridge regression models, linear discriminant analysis models, nearest neighbor models, decision tree models, perceptron models, neural network models, support vector machine models, Naive Bayes models, AdaBoost models, GBDT models, XGBoost models, LightGBM models, CatBoost models, and random forest models.
[0025] The fifth aspect of the present invention provides a diagnostic system for intervertebral disc degeneration, the system comprising: Data acquisition unit: used to acquire NME3 and LCN2 level data in subject samples.
[0026] Data classification unit: used to substitute NME3 and LCN2 level data into the diagnostic model constructed by the method according to the fourth aspect of the present invention to obtain a classification result of whether the subject has or is suspected of having intervertebral disc degeneration.
[0027] Output unit: Used to output classification results.
[0028] The sixth aspect of the present invention provides a diagnostic device or computer-readable storage medium for intervertebral disc degeneration, the device comprising a memory and a processor, the memory being used to store program instructions; the processor being used to execute the program instructions, which, when executed, are used to perform the following operations: acquiring NME3 and LCN2 level data in a sample, inputting the NME3 and LCN2 level data into a diagnostic model constructed based on the method described in the fourth aspect of the present invention, and obtaining a classification result of whether the subject has or is suspected of having intervertebral disc degeneration.
[0029] The computer-readable storage medium stores a computer program that, when executed by a processor, implements the following method: acquiring NME3 and LCN2 level data in a sample, inputting the NME3 and LCN2 level data into a diagnostic model constructed based on the method described in the fourth aspect of the present invention, and obtaining a classification result of whether the subject has or is suspected of having intervertebral disc degeneration.
[0030] Advantages and beneficial effects of the present invention: This invention achieves specific diagnosis of lumbar intervertebral disc degeneration at the molecular level by detecting the combined biomarkers NME3 and LCN2. Compared with individual biomarkers (LCN2 or NME3), the combined detection system (LCN2+NME3) provided by this invention can achieve higher sensitivity and specificity in serum samples, and effectively improves the accuracy of early detection and diagnosis of lumbar intervertebral disc degeneration, which has important significance in clinical practice. Attached Figure Description
[0031] Figure 1 The graph shows the diagnostic efficacy of NME3 combined with LCN2 for lumbar disc degeneration obtained by proteomics detection. In the graph, A is the ROC curve of the diagnostic efficacy of NME3, LCN2, and NME3+LCN2 in the training set, and B is the ROC curve of the diagnostic efficacy of NME3, LCN2, and NME3+LCN2 in the test set.
[0032] Figure 2 The graph shows the diagnostic efficacy of NME3 and LCN2 in lumbar disc degeneration obtained by ELISA. In graph A, the comparison of serum NME3 concentrations in 120 serum samples according to the Pfirrmann classification is shown. In graph B, the comparison of serum LCN2 concentrations in 120 serum samples according to the Pfirrmann classification is shown. (The samples were divided into three groups: healthy control, moderate degeneration group, and severe degeneration group. Column height represents the mean, and error bars represent the standard error.) This indicates that P < 0.05. (P < 0.001), C is the diagnostic efficacy ROC curve of the NME3, LCN2 and NME3+LCN2 joint models in the training set, and D is the diagnostic efficacy ROC curve of the NME3, LCN2 and NME3+LCN2 joint models in the test set. Detailed Implementation
[0033] In this invention, "diagnosis" refers to the discovery, judgment, or recognition of an individual's health status or condition based on one or more signs, symptoms, data, or other information relevant to that individual. An individual's health status may be diagnosed as healthy / normal (i.e., without disease or ailment) or unhealthy / abnormal (i.e., with disease or ailment or an assessment of its characteristics). Diagnosis includes, in relation to a specific disease or ailment, the early detection of the disease; the characteristics or classification of the disease; the discovery of the disease's progression, cure, or recurrence; and the discovery of the individual's response to the disease after treatment or intervention.
[0034] In this invention, "expression level" or "level" generally refers to the amount of a biomarker in a biological sample. Expression generally refers to the process by which information (e.g., gene-encoded and / or epigenetic information) is transformed into structures present and functioning in the cell. Thus, as used in this invention, expression can refer to transcription into a polynucleotide, translation into a polypeptide, or even polynucleotide and / or polypeptide modification (e.g., post-translational modification of a polypeptide). Transcribed polynucleotide fragments, translated polypeptide fragments, or polynucleotide and / or polypeptide modified fragments (e.g., post-translational modification of a polypeptide) should also be considered expressed, whether they originate from transcripts generated by alternative splicing or from degraded transcripts, or from post-translational processing of polypeptides (e.g., by proteolysis). Expressed genes include genes transcribed into polynucleotides (e.g., mRNA) and then translated into polypeptides, as well as genes transcribed into RNA but not translated into polypeptides (e.g., transport and ribosomal RNA).
[0035] In this invention, a "biomarker" refers to a substance differentially expressed between subjects with a second phenotype (e.g., no disease) and subjects with a first phenotype (e.g., disease), including genes, proteins, metabolites, or microorganisms. Specifically, it is significantly present (i.e., increased or decreased) in biological samples from subjects with a first phenotype (e.g., disease) compared to those from subjects with a second phenotype (e.g., no disease); biomarkers can be differentially present at any level. In a specific embodiment of this invention, the biomarkers refer to NME3 and LCN2.
[0036] In this invention, the "affinity reagent that specifically binds to NME3 or LCN2 protein" includes antibodies, antibody functional fragments, nucleic acid aptamers, lectins, or receptors. The antibodies or antibody functional fragments can be of any structure, size, immunoglobulin class, origin, etc., as long as they can bind to the target protein. The antibodies or antibody functional fragments described in this invention can be monoclonal or polyclonal. An antibody functional fragment refers to a portion of an antibody that retains its antigen-binding activity or a peptide containing a portion of an antibody. Antibody functional fragments can include F(ab')2, Fab', Fab, single-chain Fv (scFv), disulfide-bonded Fv (dsFv) or polymers thereof, dimerized V regions (biantibodies), or peptides containing CDRs. Antibodies can be obtained by methods known to those skilled in the art. For example, a mammalian cell expression vector that retains all or part of the target protein or integrates the polynucleotides encoding them can be prepared as an antigen. After immunizing an animal with the antigen, immune cells are obtained from the immunized animal and fused with cancer cells to obtain a hybridoma. Antibodies are then collected from the hybridoma culture. Finally, monoclonal antibodies against the marker protein can be obtained by antigen-specific purification of the obtained antibody using the marker protein or a portion thereof used as the antigen. The nucleic acid aptamer refers to a single-stranded DNA or RNA molecule that can bind to the target protein with high affinity and high specificity, obtained by screening from a random oligonucleotide library using the exponentially enriched ligand systematic evolution (SELEX) technique. Nucleic acid aptamers fold into specific three-dimensional spatial conformations (such as hairpin structures, G-quadruplexes, pseudoknots, etc.) and achieve specific binding with the target protein through non-covalent interactions such as hydrogen bonds, electrostatic interactions, van der Waals forces, and shape complementarity. Nucleic acid aptamers have advantages such as small molecular weight, convenient chemical synthesis, high batch-to-batch consistency, easy modification and labeling, and low immunogenicity, and can be used as an alternative to antibodies for the detection of biomarkers.
[0037] In some embodiments, the reagent further includes a detectable marker. The detectable marker refers to a composition capable of generating a detectable signal indicating the presence of a target polynucleotide in the sample being tested. Suitable markers include, but are not limited to, radioisotopes, nucleotide chromophores, enzymes, substrates, fluorescent molecules, chemiluminescent components, magnetic particles, and bioluminescent components. Therefore, the marker is any composition detectable by a device or method, including but not limited to spectroscopic, photochemical, biochemical, immunochemical, electrochemical, optical, chemical detection devices, or any other suitable device. In some embodiments, the marker can be detected visually without the aid of a device.
[0038] In this invention, "sample" refers to a composition obtained from or derived from a subject that contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical, and / or physiological characteristics. For example, a sample refers to any sample derived from a subject that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell cultures, cell supernatants, cell lysates, exosomes, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, serous cavity effusions (including pleural effusion, ascites, and pericardial effusion), follicular fluid, semen, pancreatic juice, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tissue culture fluid, tissue extracts, homogenized tissue, cell extracts, and combinations thereof.
[0039] In this invention, the subject refers to an individual or animal that suffers from or may suffer from the intervertebral disc degeneration-related disease described in this invention. It can also refer to an individual or animal used for a specific purpose, such as scientific research. Specifically, the individuals mentioned include, for example, animal individuals, particularly mammals, such as humans, pigs, dogs, cats, cattle, sheep, horses, mice, rats, rabbits, guinea pigs, monkeys, etc. More specifically, the individual mentioned in this invention is a human.
[0040] In this invention, verification using real clinical samples collected by this invention revealed that the combination of NME3 and LCN2 has good diagnostic efficacy for intervertebral disc degeneration. The diagnostic efficacy is verified using the receiver operating characteristic curve (ROC). The area under the curve (AUC) is the area under the ROC curve, which is well known to those skilled in the art. Measuring AUC helps to compare the accuracy of classifiers across the overall data range.
[0041] The ROC curve is a graph of the true positive rate (sensitivity) versus the false positive rate (100% - specificity) of an experiment. It is useful for depicting the performance of a specific characteristic when distinguishing between two populations. Typically, characteristic data are selected across the entire population in ascending order based on the values of a single characteristic. Then, for each value of that characteristic, the true positive and false positive rates of the data are calculated. The true positive rate is determined by counting the number of cases with values higher than that characteristic and dividing by the total number of cases. The false positive rate is determined by counting the number of controls with values higher than that characteristic and dividing by the total number of controls. While this definition refers to cases where the characteristic is higher in cases compared to controls, it also applies to cases where the characteristic is lower in cases compared to controls (in which case samples with values lower than that characteristic are counted). ROC curves can be generated with respect to individual characteristics and can also be generated with respect to other individual outputs. For example, combinations of two or more characteristics can be mathematically combined (e.g., addition, subtraction, multiplication, etc.) to provide individual sum values that can be plotted on the ROC curve. Furthermore, any combination of multiple features derived from individual output values can be plotted on a ROC curve.
[0042] In this invention, a kit refers to a set of components used to detect the expression of specific biomarkers at the gene and / or protein levels in a sample to aid in the diagnosis of whether a subject has a related disease. The kit includes a gene detection kit and a protein detection kit. The gene detection kit includes reagents or chips for detecting the transcriptional levels of the NME3 and / or LCN2 genes, and the protein detection kit includes reagents or chips for detecting the expression levels of the NME3 and / or LCN2 proteins.
[0043] In this invention, the kit further includes one or more substances from the group consisting of: containers, positive controls, negative controls, buffers, preservatives, and protein stabilizers. The components of the kit may be packaged in an aqueous medium or in a lyophilized form. Suitable containers in the kit typically include at least one vial, test tube, long-necked flask, PET bottle, syringe, or other container, in which one component can be placed, and preferably, appropriately aliquoted. When more than one component is present in the kit, the kit will typically also include a second, third, or other additional container in which the additional components are placed separately. However, different combinations of components may be contained in a single vial. The kit of this invention typically also includes a container for containing the reactants, sealed for commercial sale. Such a container may include injection-molded or blow-molded plastic containers in which the desired vials can be retained. The kit may also include instructions for use, describing how to use the kit for detection and how to use the detection results to assess tumor development and select treatment regimens.
[0044] In this invention, the chip has reagents capable of detecting and / or quantifying one or more markers or other sample-source markers immobilized at predetermined locations on a substrate. As an illustrative example, reagents immobilized at discrete predetermined locations can be provided to the chip for detecting and quantifying markers in a sample, in any quantity or combination thereof.
[0045] In this invention, the method for constructing the diagnostic model is known to those skilled in the art and can be implemented and realized in different ways, linking the expression level of a biomarker to a certain probability or risk. Preferably, the measured concentrations of the biomarker and one or more other biomarkers are mathematically combined, and the combined value is associated with the fundamental question of whether or not one has a disease. The measured biomarker values can be combined using any suitable existing mathematical method, and the diagnostic model can be constructed using machine learning algorithms.
[0046] It should be understood that the systems, apparatuses, and methods described in this invention can be implemented in other ways. For example, the apparatus embodiments described above are merely illustrative; for instance, the division of modules is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple modules or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the couplings or direct couplings or communication connections shown or discussed may be indirect couplings or communication connections through some interfaces, apparatuses, or modules, and may be electrical, mechanical, or other forms.
[0047] The modules described as separate components may or may not be physically separate. The components shown as modules may or may not be physical units; that is, they may be located in one place or distributed across multiple network units. Some or all of the units can be selected to achieve the purpose of this embodiment according to actual needs.
[0048] Furthermore, the functional modules in the various embodiments of the present invention can be integrated into one processing module, or each module can exist physically separately, or two or more modules can be integrated into one module. The integrated modules described above can be implemented in hardware or as software functional modules.
[0049] The present invention will be further illustrated below with reference to specific embodiments. These specific embodiments are for illustrative purposes only and should not be construed as limiting the invention. Those skilled in the art will understand that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and spirit of the invention. The scope of the invention is defined by the claims and their equivalents. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention pertains.
[0050] The reagents, raw materials, and experimental consumables used in this invention are readily available to those skilled in the art and, unless otherwise specified, can be obtained commercially. Experimental methods not specifying particular conditions in this invention are typically performed under conventional conditions or according to the manufacturer's recommendations. In particular, the following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way. It should be noted that the experimental conditions and results described in the following examples are for illustrative purposes only and should not, and will not, limit the invention as described in the claims.
[0051] Example 1: Validation of the diagnostic efficacy of NME3 combined with LCN2 for lumbar disc degeneration I. Experimental Methods 1. Sample Collection and Grouping: Serum samples were collected from 90 subjects who visited the orthopedic outpatient clinic or were hospitalized at Wangjing Hospital of China Academy of Chinese Medical Sciences between January 2022 and December 2024. All subjects underwent lumbar MRI examination and were divided into three groups according to the Pfirrmann MRI grading system: healthy control group (Pfirrmann I–II, intervertebral disc structure basically normal, n=30), moderate degeneration group (Pfirrmann III, n=30), and severe degeneration group (Severe, Pfirrmann IV–V, n=30). The moderate and severe degeneration groups were disease groups.
[0052] 2. Proteomics: Serum samples were subjected to SDS lysis and BCA protein concentration determination. After removing high-abundance impurity proteins using High-Select™ HSA / Immunoglobulin Depletion Mini Spin Columns, they were digested with trypsin and desalted using SOLA™ SPE. 4D-DIA mass spectrometry was performed using a TimsTof Pro mass spectrometer (Bruker) in conjunction with an Evosep One liquid chromatography system. Raw data were analyzed using Spectronaut Pulsar software, with an FDR < 0.01 used as the quality control standard for protein identification and quantification. For protein expression values below the detection limit, half of the lowest detectable value of that protein was used for filler.
[0053] 3. Diagnostic Model Construction: The serum samples were randomly divided into a training set (45 cases) and a test set (45 cases) in a 5:5 ratio. The training set included 15 healthy controls, 15 moderate degeneration groups, and 15 severe degeneration groups; the test set included 15 healthy controls, 15 moderate degeneration groups, and 15 severe degeneration groups. After log2 transformation of the original concentrations of NME3 and LCN2, receiver operating characteristic (ROC) curves were constructed using the pROC package in R language. The area under the curve (AUC) and its 95% confidence interval using the DeLong method were calculated, and the optimal diagnostic cutoff value was determined using the Youden index.
[0054] II. Experimental Results 4D-DIA proteomics analysis showed that the expression levels of NME3 and LCN2 proteins in the serum of patients with lumbar disc degeneration were significantly higher than those in healthy controls.
[0055] ROC diagnostic analysis results are as follows: Figure 1 As shown in A and 1B: (1) NME3 standalone ROC: In the training set, the AUC of NME3 serum concentration (log2 converted) distinguishing between the healthy control group and the moderate and severe degeneration groups was 0.850 (95% CI: 0.767–0.933), with a sensitivity of 70.0% and a specificity of 100.0%. In the test set, the AUC of NME3 was 0.750 (95% CI: 0.659–0.841), with a sensitivity of 50.0% and a specificity of 100.0%.
[0056] (2) LCN2 standalone ROC: In the training set, LCN2 had an AUC of 0.867 (95% CI: 0.786–0.947), a sensitivity of 73.3%, and a specificity of 100.0%. In the test set, LCN2 had an AUC of 0.887 (95% CI: 0.752–1.000), a sensitivity of 90.0%, and a specificity of 93.3%.
[0057] (3) ROC of NME3+LCN2 combined: The combined model based on logistic regression had an AUC of 0.883 (95% CI: 0.806–0.960) in the training set, with a sensitivity of 76.7% and a specificity of 100.0%. In the test set, the combined model had an AUC of 0.901 (95% CI: 0.792–1.000), with a sensitivity of 90.0% and a specificity of 93.3%. The AUC of the combined model was better than that of NME3 or LCN2 alone, especially in the test set where the AUC exceeded 0.9, indicating that the combination of the two can significantly improve diagnostic efficacy.
[0058] The above results indicate that both serum NME3 and LCN2 proteins, when detected individually, have good auxiliary diagnostic value for moderate to severe lumbar disc degeneration. Combined detection of both proteins further improves diagnostic sensitivity and overall discriminative efficacy. Notably, NME3 exhibits excellent specificity (100% in both the training and test sets), effectively excluding false positives in healthy individuals; LCN2 demonstrates superior sensitivity (90.0% in the test set), with the two proteins complementing each other. The combined model achieved an AUC of 0.901 in the test set, fully validating the superiority of their synergistic diagnostic effect.
[0059] Example 2: Secondary verification of the diagnostic efficacy of NME3 for lumbar intervertebral disc degeneration I. Experimental Methods 1. Sample Collection and Grouping: Serum samples were collected from 120 subjects who visited the orthopedic outpatient clinic or were hospitalized at Wangjing Hospital of China Academy of Chinese Medical Sciences between January 2022 and September 2026. These subjects did not overlap with the 90 subjects who underwent proteomics testing in Example 1, forming an independent validation cohort. All patients underwent lumbar spine MRI examination and were divided into three groups according to the Pfirrmann MRI grading system: healthy control group (Pfirrmann I–II, n=60), moderate degeneration group (Moderate, Pfirrmann III, n=30), and severe degeneration group (Severe, Pfirrmann IV–V, n=30). The moderate and severe degeneration groups were considered disease groups.
[0060] 2. ELISA: The concentrations of NME3 and LCN2 proteins in the above 120 serum samples were quantitatively detected using the human NME3 enzyme-linked immunosorbent assay (ELISA) kit (Abbexa, catalog number abx381828) and the human LCN2 double antibody sandwich ELISA kit (Proteintech, catalog number KE00144).
[0061] The NME3 detection steps are as follows: Thaw the serum sample at room temperature, centrifuge at 1000×g for 20 min to remove the precipitate; dilute the standard according to the kit instructions and establish a standard curve; add 100 μL each of serum sample and standard to a 96-well microplate pre-coated with NME3 capture antibody, and incubate at 37°C for 60 min; discard the liquid, add 100 μL of biotin-labeled detection antibody working solution, and incubate at 37°C for 60 min; wash the plate 3 times, add 100 μL of horseradish peroxidase (HRP)-labeled detection reagent working solution, and incubate at 37°C for 30 min; wash the plate 5 times, add 90 μL of TMB substrate chromogenic solution, and incubate at 37°C in the dark for 15 min; add 50 μL of stop solution to terminate the reaction, and measure the optical density (OD value) of each well at 450 nm using a microplate reader.
[0062] The LCN2 detection steps are as follows: Thaw the serum sample at room temperature, centrifuge at 1000×g for 15 min to remove the precipitate; dilute the standard according to the kit instructions and establish a standard curve; add 100 μL each of the 1:80 diluted serum sample and standard to a 96-well microplate pre-coated with LCN2 capture antibody, and incubate at 37°C for 120 min; discard the liquid, wash the plate 4 times, add 100 μL of HRP-labeled detection antibody working solution, and incubate at 37°C for 40 min; wash the plate 4 times, add 100 μL of TMB substrate chromogenic solution, and incubate at 37°C in the dark for 15 min; add 100 μL of stop solution to stop the reaction, and use a microplate reader to measure the optical density (OD value) of each well at a wavelength of 450 nm using 630 nm as the calibration wavelength.
[0063] The absolute concentrations (ng / mL) of NME3 and LCN2 proteins in each sample were calculated based on their respective standard curves. All samples were analyzed in duplicate.
[0064] 3. Diagnostic Model Construction: The serum samples were randomly divided into a training set (60 cases) and a test set (60 cases) in a 5:5 ratio, using the Pfirrmann classification as the stratification factor. The training set included 30 healthy controls and 30 patients with lumbar disc degeneration, while the test set included 30 healthy controls and 30 patients with lumbar disc degeneration. Based on serum NME3 and LCN2 protein concentrations, receiver operating characteristic (ROC) curves were constructed using the pROC package in R. The area under the curve (AUC) and its 95% confidence interval using the DeLong method were calculated, and the optimal diagnostic cutoff value was determined using the Youden index.
[0065] II. Experimental Results ELISA results showed that the expression levels of NME3 and LCN2 proteins in the serum of patients with lumbar disc degeneration (moderate and severe degeneration groups) were significantly higher than those in the healthy control group, consistent with the trend of the proteomics results in Example 1. Figure 2 As shown in Figures A and B, the serum NME3 concentrations (mean ± standard error) in the healthy control group, moderate degeneration group, and severe degeneration group were 1.69 ± 0.09 ng / ml, 2.11 ± 0.12 ng / ml, and 3.41 ± 0.28 ng / ml, respectively, while the serum LCN2 concentrations were 188.80 ± 8.37 ng / ml, 264.77 ± 7.44 ng / ml, and 295.07 ± 8.35 ng / ml, respectively. The concentrations of NME3 and LCN2 increased with the severity of degeneration, with the concentrations measured in ng / ml. Welch analysis of variance showed that the differences between NME3 (F=18.746, P<0.001) and LCN2 (F=42.846, P<0.001) were statistically significant among the three groups. Games-Howell post-hoc tests also showed that the differences between each pair of groups were statistically significant (NME3: healthy control group vs. moderate degeneration group P=0.0149, healthy control group vs. severe degeneration group P<0.001, moderate degeneration group vs. severe degeneration group P=0.0004; LCN2: healthy control group vs. moderate degeneration group P<0.001, healthy control group vs. severe degeneration group P<0.001, moderate degeneration group vs. severe degeneration group P=0.0238).
[0066] ROC curves were constructed based on serum NME3 and LCN2 protein concentrations. The ROC curves for the training and test sets are shown below. Figure 2 As shown in C and 2D: (1) NME3 ROC alone: In the training set, the AUC of NME3 serum concentration distinguishing healthy controls from patients with lumbar disc degeneration was 0.721 (95% CI: 0.592–0.850). In the test set, the AUC of NME3 was 0.776 (95% CI: 0.658–0.893).
[0067] (2) LCN2 standalone ROC: In the training set, the AUC of LCN2 serum concentration distinguishing healthy controls from patients with lumbar disc degeneration was 0.832 (95% CI: 0.725–0.939). In the test set, the AUC of LCN2 was 0.890 (95% CI: 0.808–0.972).
[0068] (3) ROC of NME3+LCN2 combined: The AUC of the combined model based on logistic regression was 0.968 (95% CI: 0.932–1.000) in the training set and 0.957 (95% CI: 0.910–1.000) in the test set. The AUC of the combined model was higher than that of NME3 or LCN2 alone in both the training and test sets, further verifying the superiority of the combined diagnosis.
[0069] The ELISA validation results described above are consistent with the proteomics findings in Example 1, further confirming that both serum NME3 and LCN2 proteins, when detected individually, have good auxiliary diagnostic value for lumbar disc degeneration, while their combined detection significantly improves diagnostic efficacy. Compared to proteomics detection, the ELISA method has advantages such as ease of operation, low cost, and high feasibility for clinical translation, providing a methodological basis for the clinical application of NME3 and LCN2 as combined serological diagnostic biomarkers for intervertebral disc degeneration.
[0070] The above description of the embodiments is only for understanding the method and core ideas of the present invention. It should be noted that those skilled in the art can make various improvements and modifications to the present invention without departing from the principles of the invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.
Claims
1. The application of a reagent for detecting the expression level of a combined biomarker in a sample in the preparation of products for diagnosing intervertebral disc degeneration, characterized in that, The combined biomarkers are NME3 and LCN2.
2. The application according to claim 1, characterized in that, The reagents include reagents for detecting the protein expression levels of NME3 and LCN2 in the sample, reagents for detecting the DNA levels of NME3 and LCN2 in the sample, and reagents for detecting the RNA levels of NME3 and LCN2 in the sample. Preferably, the reagents for detecting the protein expression levels of NME3 and LCN2 in the sample include reagents for detecting the expression levels of NME3 and LCN2 using proteomics technology, and affinity reagents that specifically bind to NME3 or LCN2 proteins; Preferably, the affinity reagent includes an antibody, an antibody fragment, or a nucleic acid aptamer; Preferably, the reagents for detecting the DNA levels of NME3 and LCN2 in the sample include reagents for detecting the DNA levels of NME3 and LCN2 and their molecular modification levels (including DNA methylation level, DNA hydroxymethylation level, histone acetylation level, etc.); Preferably, the reagents for detecting the RNA levels of NME3 and LCN2 in the sample include reagents for detecting the expression levels of mRNA, lncRNA, circRNA, and / or miRNA of NME3 and LCN2 in the sample.
3. The application according to claim 1, characterized in that, The intervertebral disc degeneration includes cervical intervertebral disc degeneration, lumbar intervertebral disc degeneration, and thoracic intervertebral disc degeneration; Preferably, the intervertebral disc degeneration is lumbar intervertebral disc degeneration.
4. The application according to claim 1, characterized in that, The samples include tissues, cells, body fluids, and exosomes derived from the subjects; Preferably, the body fluid samples include blood samples, serous cavity effusion samples, cerebrospinal fluid samples, lymph fluid samples, synovial fluid samples, urine samples, saliva samples, sputum samples, and tear samples; Preferably, the serous cavity effusion sample includes pleural effusion sample, ascites sample, and pericardial effusion sample; Preferably, the sample is a blood sample from the subject; Preferably, the sample is a serum sample from the subject.
5. A product for diagnosing intervertebral disc degeneration, characterized in that, The product includes the reagent as described in claim 2; Preferably, the product includes a reagent kit, a chip, and a test strip.
6. The application of combined biomarkers in constructing a diagnostic model for intervertebral disc degeneration, characterized in that, The combined biomarkers are NME3 and LCN2.
7. A method for constructing a diagnostic model for intervertebral disc degeneration, characterized in that, The method includes obtaining NME3 and LCN2 level data in the sample and inputting the data into a machine learning algorithm to construct a diagnostic model. Preferably, the method includes the following steps: dividing the NME3 and LCN2 level data into training and test sets, extracting the NME3 and LCN2 level data from the training set and inputting them into a machine learning algorithm to construct a diagnostic model, and validating the model through the test set to evaluate its performance.
8. The method according to claim 7, characterized in that, The machine learning algorithms include algorithm models developed using various development tools; Preferably, the development tools include TensorFlow, Scikit-Learn, PyTorch, OpenNN, RapidMiner, Azure Machine Learning, Apache Mahout, Shogun, KNIME, Vertex AI, H2Oai, Anaconda, Keras, Tableau, Fast.ai, Catalyst, Amazon ML, MLJAR, and Spell. Preferably, the algorithm model includes linear regression model, logistic regression model, Lasso regression model, Ridge regression model, linear discriminant analysis model, nearest neighbor model, decision tree model, perceptron model, neural network model, support vector machine model, Naive Bayes model, AdaBoost model, GBDT model, XGBoost model, LightGBM model, CatBoost model, and random forest model.
9. A diagnostic system for intervertebral disc degeneration, characterized in that, The system includes: Data acquisition unit: used to acquire NME3 and LCN2 level data in subject samples; Data classification unit: used to substitute NME3 and LCN2 level data into the diagnostic model constructed according to the method of claim 7 or 8 to obtain a classification result of whether the subject has or is suspected of having intervertebral disc degeneration; Output unit: Used to output classification results.
10. A diagnostic device or computer-readable storage medium for intervertebral disc degeneration, characterized in that, The device includes a memory and a processor. The memory is used to store program instructions. The processor is used to execute the program instructions. When the program instructions are executed, the processor is used to perform the following operations: acquire NME3 and LCN2 level data in the sample, input the NME3 and LCN2 level data into a diagnostic model constructed based on the method of claim 7 or 8, and obtain a classification result of whether the subject has or is suspected of having intervertebral disc degeneration. The computer-readable storage medium stores a computer program that, when executed by a processor, implements the following method: acquiring NME3 and LCN2 level data in a sample, inputting the NME3 and LCN2 level data into a diagnostic model constructed based on the method of claim 7 or 8, and obtaining a classification result of whether the subject has or is suspected of having intervertebral disc degeneration.
